Independent coverage of the sessions, sectors, and companies moving European markets.
Independent coverage of the sessions, sectors, and companies moving European markets.
Independent coverage of the sessions, sectors, and companies moving European markets.
Short positions on Moderna incurred losses as the biotech stock surged to a new high.
Short sellers in Moderna faced losses exceeding $4.8 billion following a sharp increase in the company’s stock price. The surge marked a record high for the biotech firm’s shares.
Further verified details on the drivers behind the stock’s rise were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →Follow Finance Review Daily for markets, economy, and company coverage as it happens.
A short, daily brief on the moves that matter — markets, macro, and the stories behind them.